Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option-Reference-Cited by-同舟云学术

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option

Published:2019-05 Issue:5 Volume:30 Page:721-732
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Buechel M.,Herzog T.J.,Westin S.N.^ORCID,Coleman R.L.,Monk B.J.,Moore K.N.

Funder

J & J

Clovis

AstraZeneca

Tesaro

Roche

Caris

Merck

Pfizer

Novartis

Takeda

Roche/Genentech

Janssen

OncoMed

Esperance

AbbVie

PTC Therapeutics

Lilly

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz104/28566108/mdz104.pdf

Reference86 articles.

1. American Cancer Society. Cancer Facts and Figures 2018. Atlanta, GA 2018. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html.

2. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer;Alvarez;Gynecol Oncol,2016

3. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease;Wilson;Ann Oncol,2017

4. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma;Chi;Cancer,2006

5. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial;Harter;Ann Surg Oncol,2006

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review;Future Oncology;2024-08-12

2. FXN targeting induces cell death in ovarian cancer stem-like cells through PRDX3-Mediated oxidative stress;iScience;2024-08

3. Unraveling the role of tissue colonized microbiome in ovarian cancer progression;Computers in Biology and Medicine;2024-07

4. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2024-06-27

5. Combined aqupla, paclitaxel liposome, and docetaxel treatment: survival and biomarker outcomes in recurrent ovarian cancer patients;Frontiers in Oncology;2024-06-17